NMPA accepted Akeso’s ebronucimab (PCSK9) marketing application in two cardiovascular indications

HONG KONG, June 1, 2023 /PRNewswire/ — Akeso Inc. (9926. HK, “Akeso”) announced today that China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for its fully human anti-PCSK9 monoclonal antibody ebronucimab (AK102) for 2 indications 1) primary hypercholesterolemia and mixed hyperlipidemia, and 2) heterozygous familial hypercholesterolemia (HeFH). Ebronucimab is jointly developed … Read more